The Year in Biotech and What’s Ahead for 2026

Episode Summary

Executive Summary: Adam Feuerstein and Daniel Levine review biotech’s dramatic 2025 rebound: XBI surged, dealmaking roared back, and financing improved as policy fears eased and rates fell. They argue much of the sector’s strength reflects sentiment, M&A, and obesity-drug optimism, while warning that FDA turmoil and research funding cuts could become more damaging in 2026.

Main Topics: Biotech stock rebound in 2025 (Priority: 5/5): The XBI and broader biotech equities staged a major recovery after a bleak start, with gains driven by improving sentiment, financing, and selective company-level wins across sizes and subsectors. Dealmaking and capital rotation (Priority: 5/5): A surge in M&A, including multiple multibillion-dollar acquisitions, helped reset investor confidence and recycled capital back into the sector, especially among specialist funds. FDA instability and regulatory risk (Priority: 5/5): The transcript highlights chaos, staffing losses, and leadership turnover at the FDA, with concern that the consequences may finally show up in slower reviews and more controversial decisions in 2026. Obesity/GLP-1 as a dominant growth theme (Priority: 4/5): GLP-1 drugs remain a major driver of valuation, dealmaking, and pipeline attention, with the next wave centered on oral GLP-1s and newer weight-loss mechanisms. Mixed year for drug innovation and approvals (Priority: 4/5): Although approvals were numerically solid, the speakers view 2025 as an average innovation year, with more attention drawn to setbacks and safety issues than to standout launches. Company-specific winners and losers (Priority: 4/5): Pfizer, Novo Nordisk, Moderna, and Sarepta illustrate the range of strategic challenges in the sector, from patent cliffs and obesity-race pressure to political backlash and safety crises. 2026 outlook and JPMorgan conference expectations (Priority: 3/5): Expectations for JPM 2026 are higher than last year after a strong run-up, but the speakers caution that deal flow may pause and that stock performance could cool temporarily.

Key Arguments: Biotech’s 2025 rally was unusually sharp, with sentiment shifting from despair to optimism in a matter of months. Policy fears around tariffs and drug pricing proved less damaging than feared; MFN agreements with the White House did not materially hurt guidance. Lower interest rates and expectations of further cuts are a meaningful tailwind for cash-burning biotech companies. M&A was a major confidence booster because acquired-company proceeds are often redeployed into the sector. FDA dysfunction may not have fully hit approvals yet, but staffing losses and inconsistent decision-making could start to affect timelines and outcomes in 2026. Obesity remains the field’s most powerful commercial and strategic theme, with oral GLP-1s and alternative weight-loss mechanisms driving the next phase. Many large pharma companies still need external innovation to offset patent cliffs, making biotech assets attractive acquisition targets. Long-term cuts to NIH and research funding could slow the upstream innovation engine even if the near-term market impact is muted.

Data Points: XBI year-to-date performance: up 37% - Current performance cited during the year-end biotech market review XBI performance in early April: down 22% for the year - Shows how severe the sector’s low point was before the rebound Biotech rebound timing: roughly from early April to year-end - Feuerstein describes the recovery as a near-straight-line move upward after the trough Deal value: BioMarin/Amicus: $4.8 billion - Acquisition announced the morning of the interview Deal value: Johnson & Johnson / Intra-Cellular Therapies: $14.6 billion - Cited as one of the largest biotech deals of 2025 Deal value: Novartis / Avidity: $12 billion - Highlighted among the year’s major M&A transactions Deal value: Merck / Verona Pharma: $10 billion - Another major acquisition contributing to the M&A boom Deal value: Pfizer / Metsera: more than $10 billion - Used as an example of competitive bidding for obesity assets Novel therapies approved in 2025: about 50 - Feuerstein describes approvals as solid in number but not especially standout in quality Eli Lilly market capitalization: $1 trillion - Lilly became the first healthcare company to reach this valuation, driven by obesity drugs Company count with MFN agreements: 7-9 companies - Referenced as recent pharma/biotech firms reaching pricing agreements with the Trump White House Best M&A year comparison: best since 2019 - Feuerstein says 2025 was the strongest biotech M&A year in several years

Pivotal Quotes: "It’s really remarkable because if you think back to early April, the XBI... was down 22% for the year... right now... the XBI is up 37% for the year." — Adam Feuerstein: Describing the magnitude of biotech’s 2025 stock reversal "The FDA is kind of a dumpster fire." — Adam Feuerstein: Expressing concern about agency instability and leadership turnover "Biotech stocks have benefited from people sort of kicking the worries and the concerns down the road." — Adam Feuerstein: Explaining why regulatory and policy risks have not yet fully weighed on the sector

Implications: Biotech enters 2026 with stronger sentiment, more M&A optionality, and obesity-driven enthusiasm, but investors should watch for FDA dysfunction, a possible dealmaking pause, and long-lag damage from science funding cuts.